Professor Francisco Leyva
Introduction
Cardiac resynchronisation therapy (CRT) is a standard treatment for patients with heart failure (HF), impaired left ventricular (LV) function and a wide QRS complex. The therapy emerged following the recognition that disturbances in inter- and intra-ventricular conduction contribute to LV dysfunction. Since its first clinical use,1,2 robust evidence from randomised-controlled trials (RCTs) has supported its use in patients with severe and mild HF. In combination with defibrillation (CRT-D), CRT reduces mortality from pump failure and sudden, arrhythmic cardiac death (SCD).
Since the last RCTs on CRT,3 th
